Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Sarepta Therapeutics Inc (NASDAQ:SRPT)

62.24
Delayed Data
As of 3:59pm ET
 +3.14 / +5.31%
Today’s Change
8.00
Today|||52-Week Range
63.73
+61.33%
Year-to-Date
Summit (SMMT): Rare Pediatric Disease Status for DMD Drug
6:21pm / Zacks.com - Paid Partner Content
Sarepta jumps after drugs regulator boost
Sep 20 / FT.com - Paid Partner Content
Better Buy: BioMarin Pharmaceuticals Inc. vs. Sarepta Therapeutics Inc
12:24pm / MotleyFool.com - Paid Partner Content
Was Sarepta's Big Win a Big Mistake for the FDA?
Sep 20 / MotleyFool.com - Paid Partner Content
Selling Into Strength Can Be a Great Strategic Move
11:23am / TheStreet.com - Paid Partner Content
Here's Why Sarepta Therapeutics, Inc's Stock is Jumping Again
Sep 20 / MotleyFool.com - Paid Partner Content
Sarepta Therapeutics (SRPT) Stock Climbs, Analysts Bullish on Exondys
10:20am / TheStreet.com - Paid Partner Content
Does Sarepta Therapeutics Inc.'s FDA Win Make Shares a Buy?
Sep 20 / MotleyFool.com - Paid Partner Content
3 Stocks to Avoid in Healthcare
8:05am / MotleyFool.com - Paid Partner Content
Company News for September 20, 2016
Sep 20 / Zacks.com - Paid Partner Content
There's No Debate, Dip Buyers Are Jittery
Sep 26 / TheStreet.com - Paid Partner Content
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Sep 20 / Zacks.com - Paid Partner Content
For Traders, Planning Is More Important Than the Plan
Sep 25 / TheStreet.com - Paid Partner Content
Why PTC Therapeutics Shares Skyrocketed 20.6% Today
Sep 19 / MotleyFool.com - Paid Partner Content
The Woman Behind Sarepta Therapeutics' Success
Sep 24 / MotleyFool.com - Paid Partner Content
Why Sarepta Pharmaceuticals, Tech Data, and Cliffs Natural Resources Jumped Today
Sep 19 / MotleyFool.com - Paid Partner Content
2 Stocks I'd Never Buy, and 1 I'll Consider
Sep 23 / MotleyFool.com - Paid Partner Content
Why Sarepta Therapeutics Soared 74% Today
Sep 19 / MotleyFool.com - Paid Partner Content
5 Stocks With Amazon-Like Growth Potential
Sep 22 / MotleyFool.com - Paid Partner Content
Pulte, Lennar and DR Horton rise on strong US builder sentiment
Sep 19 / FT.com - Paid Partner Content
I Am One of the Underinvested Bulls Right Now
Sep 22 / TheStreet.com - Paid Partner Content
Sarepta shares surge 90% on FDA approval
Sep 19 / FT.com - Paid Partner Content
Stock Futures Rise as Wall Street Finds Relief in a Patient Fed
Sep 22 / TheStreet.com - Paid Partner Content
Why Apogee Enterprises, Ferrellgas Partners, and Sarepta Therapeutics Slumped Today
Sep 15 / MotleyFool.com - Paid Partner Content
Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD ...
Sep 21 / Zacks.com - Paid Partner Content
Sarepta Shares Soar on News of Key Drug Critic FDA Exit
Sep 15 / Zacks.com - Paid Partner Content
Why PTC Therapeutics, Inc. Gave Back As Much As 10% on Tuesday
Sep 20 / MotleyFool.com - Paid Partner Content
Here's Why Sarepta Therapeutics Inc. is Falling Today
Sep 15 / MotleyFool.com - Paid Partner Content
Forget Sarepta Therapeutics, Here Are 3 Other Biotech Stocks to Buy
Sep 20 / MotleyFool.com - Paid Partner Content
Company News for September 15, 2016
Sep 15 / Zacks.com - Paid Partner Content